KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted): 2010-2024

Historic EPS (Weighted Average and Diluted) for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Dec 2024 value amounting to $38.34.

  • Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) rose 18.02% to $13.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $41.81, marking a year-over-year increase of 3.44%. This contributed to the annual value of $38.34 for FY2024, which is 10.27% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $38.34, which was up 10.27% from $34.77 recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $71.97 in FY2021 and a low of $30.52 during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of $38.22 in 2022 and averaged $37.11.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 135.81% in 2021, and later plummeted by 46.89% in 2022.
  • Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at $30.52 in 2020, then soared by 135.81% to $71.97 in 2021, then plummeted by 46.89% to $38.22 in 2022, then decreased by 9.03% to $34.77 in 2023, then rose by 10.27% to $38.34 in 2024.